Category: Uncategorized

  • TB-500 Fragment

    Synthetic heptapeptide fragment of thymosin beta-4 encompassing the actin-binding domain (residues 17-23) with N-terminal acetylation

    A synthetic N-acetylated heptapeptide (Ac-LKKTETQ) derived from the central actin-binding domain of thymosin beta-4, investigated for tissue repair, angiogenesis, anti-inflammatory activity, and wound healing through modulation of actin polymerization dynamics and cellular migration.

    Abstract

    TB-500 Fragment (Ac-LKKTETQ) is a synthetic heptapeptide corresponding to residues 17 through 23 of the endogenous 43-amino acid polypeptide thymosin beta-4, a ubiquitous intracellular G-actin sequestering protein that participates in cytoskeletal organization, cell migration, angiogenesis, and tissue repair. The fragment encompasses the central actin-binding domain of the parent molecule and is N-terminally acetylated to confer resistance to aminopeptidase degradation and to replicate the post-translational modification present on native thymosin beta-4. TB-500 Fragment has been the subject of substantial preclinical investigation since the early 2000s, when Philp et al. (2003) demonstrated that the synthetic LKKTETQ heptapeptide promoted dermal wound repair in db/db diabetic mice and in aged mice at efficacy levels comparable to the full-length thymosin beta-4 molecule, establishing the actin-binding domain as a sufficient pharmacophore for the tissue repair activity of the parent protein. The principal molecular mechanism of TB-500 Fragment is sequestration of G-actin monomers and modulation of actin polymerization dynamics, which promotes cell migration, endothelial tube formation, keratinocyte mobilization, and extracellular matrix remodeling. Downstream signaling involves activation of integrin-linked kinase (ILK), phosphorylation of Akt/protein kinase B, suppression of NF-kappaB-mediated proinflammatory cytokine release, and upregulation of matrix metalloproteinases that facilitate tissue remodeling during wound repair. The pharmacological profile of TB-500 Fragment is therefore characterized by four principal activities: promotion of angiogenesis, acceleration of wound healing, anti-inflammatory modulation, and facilitation of stem and progenitor cell migration. Preclinical evidence in rodent models has demonstrated accelerated dermal wound closure in diabetic and aged animals, cardioprotection following experimental myocardial infarction (demonstrated with the parent thymosin beta-4 molecule in the landmark Bock-Marquette et al. 2004 Nature study), promotion of hair follicle stem cell activation and hair growth (Philp et al. 2004), and anti-inflammatory activity through suppression of NF-kappaB nuclear translocation and reduction of TNF-alpha and IL-1-beta production. Human clinical data for the heptapeptide fragment itself are limited; the majority of clinical evidence derives from the full-length thymosin beta-4 molecule, which has been evaluated in Phase 2 and Phase 3 clinical trials for dry eye disease (RGN-259, RegeneRx Biopharmaceuticals) and in Phase 2 studies for neurotrophic keratopathy. The Phase 2 dry eye trial demonstrated statistically significant improvements in ocular discomfort (35.1 percent reduction) and corneal fluorescein staining (59.1 percent reduction) relative to vehicle control. The Phase 3 ARISE program in dry eye disease did not meet co-primary endpoints, though statistically significant improvement in ocular grittiness was observed. TB-500 Fragment is not approved by any regulatory authority for human therapeutic use. It is classified as a prohibited substance by the World Anti-Doping Agency under Sections S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is prohibited in equine racing competition by multiple national racing authorities. Pharmacokinetic data from preclinical studies indicate a plasma elimination half-life of approximately 1.5 to 3 hours following subcutaneous administration, with subcutaneous bioavailability of approximately 60 to 80 percent relative to intravenous dosing; tissue-level effects persist substantially longer than plasma residence, consistent with the intracellular mechanism of action. The compound is supplied as a lyophilized powder and is reconstituted in bacteriostatic water for injection; it is stable at refrigerated conditions for up to 30 days after reconstitution. This monograph reviews the chemistry, synthesis, and structural characterization of TB-500 Fragment; the molecular pharmacology of actin sequestration, ILK activation, and NF-kappaB suppression; the pharmacokinetic profile; the preclinical evidence base across wound healing, cardiac repair, hair growth, and anti-inflammatory models; the clinical evidence derived from the parent thymosin beta-4 molecule; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse event and safety signal assessment; and a comparative evaluation of five alternative tissue repair and regenerative peptides against TB-500 Fragment on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1451Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Piracetam

    Plain-language summaryIntrigue 65 / 100

    Piracetam is the original racetam, synthesized in 1964 and the prototype of the entire nootropic concept. It was developed at UCB Pharma and is approved in many countries for cognitive impairment. It is the lowest-potency racetam with minimal side effects, often used as a starting point for racetam research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    2-Oxopyrrolidine acetamide nootropic and positive allosteric modulator of AMPA-type glutamate receptors

    A cyclic GABA derivative synthesized at UCB Pharma as the prototype nootropic agent, distinguished by positive allosteric modulation of AMPA receptors, restoration of membrane fluidity under hypoxic and aging conditions, inhibition of platelet aggregation, and a six-decade clinical record spanning cortical myoclonus, age-related cognitive decline, and acute ischemic stroke.

    Abstract

    Piracetam (2-oxo-1-pyrrolidineacetamide), the founding member of the racetam class and the first compound for which the term “nootropic” was coined, is a cyclic derivative of gamma-aminobutyric acid (GABA) that lacks direct GABAergic receptor activity and instead exerts its principal pharmacological effects through positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptors, restoration of neuronal membrane fluidity, inhibition of voltage-gated N-type calcium channels, and rheological modification of erythrocyte and platelet function. Synthesized in 1964 by Corneliu Giurgea at the Belgian pharmaceutical company UCB under the development code UCB 6215, piracetam was initially investigated as a GABA-related sedative-hypnotic but was rapidly recognized to possess a pharmacological profile fundamentally distinct from GABA agonism: it enhanced learning and memory in animal models without producing sedation, anxiolysis, or anticonvulsant activity at therapeutic doses, and it exhibited an exceptionally favorable safety profile with no identified lethal dose in standard rodent toxicology. Giurgea formalized this novel pharmacological category in 1972 by coining the term “nootropic” from the Greek nous (mind) and trepein (to bend), establishing criteria that included enhancement of learning and memory, protection of the brain against physical or chemical injury, enhancement of cortical and subcortical control mechanisms, and absence of the pharmacological profile of typical psychotropic drugs. The molecular pharmacology of piracetam centers on a weak but functionally relevant positive allosteric modulation of AMPA receptors, characterized crystallographically by Ahmed and Oswald (2010) as binding at a novel site along the AMPA receptor dimer interface distinct from the aniracetam and cyclothiazide binding sites [1]. At concentrations achieved by standard oral dosing (approximately 100 micromolar in cerebrospinal fluid after a 1200 mg oral dose), piracetam enhances AMPA receptor-mediated calcium influx, reduces receptor desensitization, and facilitates glutamatergic neurotransmission in cortical and hippocampal circuits. A second major mechanism is the restoration of membrane fluidity in aged, hypoxic, or otherwise compromised neuronal membranes through direct interaction with the phospholipid bilayer headgroup region, improving the mobility and function of membrane-embedded receptors and ion channels [2]. A third mechanism, inhibition of voltage-gated N-type calcium channels at low micromolar concentrations (IC50 approximately 3 micromolar in rat cortical neurons), contributes to neuroprotective activity under ischemic conditions [3]. Pharmacokinetics are characterized by near-complete oral absorption (bioavailability approaching 100 percent), absence of hepatic metabolism (no metabolites have been identified in any species), renal excretion of the unchanged compound accounting for greater than 98 percent of the administered dose, and a plasma elimination half-life of approximately 5 hours in adults with normal renal function [4, 5]. The cerebrospinal fluid half-life is approximately 8 hours, consistent with the sustained central nervous system activity observed clinically. The pharmacokinetic profile is uncomplicated by cytochrome P450 interactions, protein binding effects, or hepatic disease sensitivity; the sole clinically relevant pharmacokinetic modifier is renal function, with dose adjustment required in renal impairment and the half-life extending to approximately 59 hours in anuric end-stage renal disease. The clinical evidence base spans six decades and multiple indications. The strongest evidence supports the use of piracetam in cortical myoclonus, where it is approved in the United Kingdom and several European jurisdictions at high doses (7.2 to 24 grams per day) as adjunctive therapy, with randomized controlled trial evidence demonstrating significant improvement in motor disability, functional capacity, and global assessment scores [6, 7]. A second major clinical application is age-related cognitive decline and dementia, where a 2002 meta-analysis of 19 double-blind placebo-controlled trials by Waegemans et al. reported a global effect favoring piracetam across a heterogeneous population of older patients with cognitive impairment [8], while a 2012 Cochrane systematic review by Flicker and Grimley Evans concluded that the evidence was suggestive but insufficient to support routine clinical use in dementia [9]. A more recent 2024 systematic review and meta-analysis by Fang et al. of 18 studies and 886 patients reported mixed findings, with some measures of cognitive function showing benefit but overall memory outcomes failing to reach clinical significance [10]. A third clinical application, acute ischemic stroke, was studied in the Piracetam in Acute Stroke Study (PASS), a multicenter randomized trial of 927 patients receiving 12 grams intravenously within 12 hours of stroke onset, which did not demonstrate significant benefit on the primary endpoint but showed a signal of efficacy in the subgroup treated within 7 hours [11, 12]. The compound is well tolerated. The principal safety considerations are dose-dependent inhibition of platelet aggregation with prolongation of bleeding time at high doses (a class effect that warrants caution in patients with hemorrhagic risk factors, concurrent anticoagulant therapy, or pre-surgical status), and the requirement for gradual dose tapering in myoclonus patients to avoid withdrawal-related seizure exacerbation [13]. Common adverse events are mild and include nervousness, hyperkinesia, somnolence, and weight gain, with no organ toxicity identified in chronic dosing studies extending to years of treatment. The compound is not approved by the United States Food and Drug Administration and is classified as a dietary supplement ingredient or research compound in the United States; it is a registered prescription medicine in over 60 jurisdictions worldwide. This monograph reviews the chemistry, synthesis, and structural class of piracetam; the molecular pharmacology at AMPA receptors, neuronal membranes, and calcium channels; the comprehensive pharmacokinetic record; the clinical evidence base across myoclonus, cognitive impairment, stroke, and additional indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five racetam-class alternatives against piracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1425Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Alpha-GPC

    Plain-language summaryIntrigue 64 / 100

    Alpha-GPC is a phospholipid that delivers choline to the brain efficiently. It supports acetylcholine production and is one of the more bioavailable choline supplements. Used in nootropic stacks alongside racetams to prevent the headaches some users experience from racetam-induced choline depletion. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Phospholipid-derived cholinergic precursor and acetylcholine biosynthetic substrate

    A high-bioavailability choline donor derived from phosphatidylcholine hydrolysis, developed in Italy as a prescription cholinergic agent for cognitive impairment and cerebrovascular disease, distinguished from other choline sources by efficient blood-brain barrier penetration and dual contribution of choline for acetylcholine synthesis and glycerophosphate for membrane phospholipid remodeling.

    Abstract

    Alpha-GPC (L-alpha-glycerylphosphorylcholine; choline alfoscerate; sn-glycero-3-phosphocholine; CAS 28319-77-9; molecular formula C8H20NO6P; molecular weight 257.22 g/mol) is an endogenous phospholipid intermediate in the deacylation pathway of membrane phosphatidylcholine and an exogenous cholinergic precursor that delivers bioavailable choline across the blood-brain barrier more efficiently than choline salts, choline bitartrate, or lecithin. The compound contains approximately 40 percent choline by mass, is freely water-soluble, highly hygroscopic, and is metabolized by phosphodiesterases in the intestinal mucosa and in central and peripheral tissues to yield free choline and glycerol-3-phosphate. The released choline serves as the immediate biosynthetic substrate for choline acetyltransferase-catalyzed acetylcholine synthesis in cholinergic neurons, while the glycerophosphate moiety enters the Kennedy pathway for phosphatidylcholine resynthesis, providing simultaneous support for neurotransmitter production and neuronal membrane integrity.

    Alpha-GPC was first synthesized by Baer and Kates in 1948 and entered pharmaceutical development in Italy in the 1980s under the trade names Gliatilin and Delecit. It is registered as a prescription medicine in Italy, Russia, and several Eastern European and Asian jurisdictions for the treatment of cognitive impairment associated with Alzheimer disease, cerebrovascular disease, and post-stroke cognitive decline. In the United States it is classified as a dietary supplement and is not regulated as a drug. The compound has accumulated a substantial clinical evidence base across multiple indications: a 2044-patient Italian multicenter trial in acute cerebrovascular disease (Barbagallo Sangiorgi et al. 1994); the De Jesus Moreno (2003) 261-patient multicenter randomized double-blind placebo-controlled trial demonstrating significant improvement on the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), and Global Deterioration Scale (GDS) at 1200 mg/day for 180 days in mild-to-moderate Alzheimer dementia; multiple open-label and controlled studies of combination therapy with acetylcholinesterase inhibitors; and recent systematic reviews and meta-analyses (Sagaro et al. 2023) confirming efficacy in adult-onset cognitive dysfunction with pooled effect sizes favoring alpha-GPC over placebo and over citicoline in head-to-head comparisons. Additional research applications include augmentation of growth hormone secretion during resistance exercise (Ziegenfuss et al. 2008), enhancement of peak force production in trained athletes, and investigation of motivational and attentional endpoints in healthy volunteers.

    Pharmacokinetics are characterized by rapid oral absorption with peak plasma choline elevation at approximately 1 to 2 hours, a choline elevation half-life of 4 to 8 hours, oral bioavailability exceeding 40 percent for choline delivery, and metabolism through phosphodiesterase-mediated hydrolysis rather than cytochrome P450-dependent pathways. The compound distributes widely, with particular concentration in brain, liver, and kidney. Excretion is predominantly renal as polar choline metabolites and expired carbon dioxide from betaine oxidation.

    The safety profile at registered doses (400 to 1200 mg/day) is favorable; the most commonly reported adverse events are mild gastrointestinal disturbance (nausea, heartburn, diarrhea), headache, and insomnia, occurring at rates modestly above placebo. A 2021 Korean retrospective cohort study (Lee et al. 2021) raised a signal for increased stroke risk with long-term alpha-GPC use, a finding that requires replication and mechanistic investigation. The proposed mechanism involves conversion of choline to trimethylamine by gut microbiota, hepatic oxidation to trimethylamine N-oxide (TMAO), and TMAO-mediated promotion of atherosclerosis and thrombosis. This signal has not been confirmed in prospective controlled trials and does not apply to short-term or moderate-dose use.

    This monograph documents the chemistry, synthesis, and preparation of alpha-GPC; the cholinergic precursor mechanism and downstream pharmacology; comprehensive pharmacokinetics; the clinical evidence base across cognitive, cerebrovascular, sport-performance, and adjunctive indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and safety signal; and a structured comparative assessment of five alternative choline donors and cholinergic precursors (citicoline, choline bitartrate, phosphatidylcholine, DMAE, and centrophenoxine) against alpha-GPC on five standards: bioavailability, effect size, clinical validation, side-effect profile, and overall utility.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1443Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Aniracetam

    Plain-language summaryIntrigue 62 / 100

    Aniracetam is a more potent racetam approved in Europe and Asia. It modulates AMPA glutamate receptors, slowing receptor desensitization, and is reported to have anxiolytic effects beyond cognition. Fat-soluble (best absorbed with food). Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Pyrrolidinone-class positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with secondary cholinergic, dopaminergic, and serotonergic neuromodulatory activity

    A lipophilic racetam nootropic developed at Hoffmann-La Roche as a cognition enhancer for cerebrovascular and neurodegenerative disorders, distinguished from piracetam by higher potency, oral lipophilicity, AMPA receptor positive allosteric modulation, and multi-target downstream activation of cholinergic, dopaminergic, and serotonergic neurotransmission through pharmacologically active metabolites.

    Abstract

    Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone; Ro 13-5057) is a lipophilic pyrrolidinone derivative of the racetam structural class, originally synthesized at Hoffmann-La Roche in the late 1970s as a more potent and centrally bioavailable analog of piracetam for the treatment of cognitive dysfunction associated with cerebrovascular disease and neurodegenerative dementia. The compound is classified as a positive allosteric modulator (PAM) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor, a mechanism that slows both channel deactivation and receptor desensitization at synaptic AMPA receptors, thereby prolonging excitatory postsynaptic currents and enhancing glutamatergic neurotransmission in cortical and hippocampal circuits critical for learning and memory [1, 2]. Beyond the direct AMPA receptor modulation, aniracetam and its principal active metabolite N-anisoyl-gamma-aminobutyric acid (N-anisoyl-GABA, which accounts for 70 to 80 percent of the metabolic disposition) exert downstream effects on multiple neurotransmitter systems: enhancement of acetylcholine release in the prefrontal cortex and hippocampus via group II metabotropic glutamate receptor modulation; site-specific activation of dopaminergic and serotonergic transmission in the mesocorticolimbic pathway through nicotinic acetylcholine receptor mechanisms; and anxiolytic activity mediated through an interaction between cholinergic, dopaminergic, and serotonergic systems [3, 4, 5]. The pharmacokinetic profile of aniracetam is characterized by rapid and complete gastrointestinal absorption, extremely low systemic bioavailability of the parent compound (approximately 0.2 percent) due to extensive first-pass hepatic hydrolysis, and a plasma elimination half-life of approximately 35 minutes [6, 7]. The parent compound is rapidly cleaved to yield three primary metabolites: N-anisoyl-GABA (70 to 80 percent), 2-pyrrolidinone (20 to 30 percent), and p-anisic acid (20 to 30 percent), each of which has been shown to contribute to the pharmacological activity profile [8]. The clinical evidence base for aniracetam derives principally from two double-blind, placebo-controlled multicenter trials in elderly patients with mild to moderate senile dementia of the Alzheimer type (SDAT), in which aniracetam at 1500 mg per day for six months produced statistically significant improvement in cognitive and psychobehavioral parameters relative to placebo and, in one trial, relative to piracetam at 2400 mg per day [9, 10]. A comparative open-label study in 276 patients with cognitive disorders demonstrated preservation of neuropsychological parameters for at least 12 months with aniracetam monotherapy and performance comparable to or exceeding cholinesterase inhibitor monotherapy in mildly demented patients [11]. Preclinical pharmacology is extensive and demonstrates cognitive enhancement in scopolamine-induced amnesia, cerebral ischemia, and age-related cognitive decline models; anxiolytic activity in elevated plus-maze, conditioned fear, and social interaction paradigms; neuroprotection against excitotoxicity and ischemic injury; and activation of brain-derived neurotrophic factor synthesis [12, 13, 14]. The compound was marketed as a prescription medicine in Japan (Draganon, subsequently withdrawn), in Italy (Ampamet), and in Greece (Memodrin, Referan) for cognitive impairment associated with cerebrovascular disease and neurodegenerative conditions. It is not approved by the United States Food and Drug Administration and is not a controlled substance in the United States, where it is sold as a research compound. This monograph reviews the chemistry, synthesis, and structural pharmacology of aniracetam; the multi-target mechanism of action spanning AMPA receptor modulation, metabotropic glutamate receptor effects, and monoaminergic neuromodulation; the comprehensive pharmacokinetic record including active metabolite characterization; the preclinical pharmacology across cognitive, anxiolytic, and neuroprotective domains; the clinical evidence base in dementia and cognitive impairment; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety; and a comparative assessment of five racetam and ampakine alternatives against aniracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1426Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pramiracetam

    Plain-language summaryIntrigue 55 / 100

    Pramiracetam is a more potent piracetam analog with strong effects on hippocampal acetylcholine release. It is used in Italy for neurological disorders and is popular in nootropic communities for memory enhancement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Diisopropylaminoethyl 2-oxopyrrolidineacetamide racetam nootropic with selective high-affinity choline uptake potentiation

    A lipophilic piracetam analog developed at Parke-Davis as a cognition-enhancing agent, distinguished from the parent racetam by potent modulation of hippocampal high-affinity choline uptake and marketed in select European jurisdictions for age-related cognitive impairment and attention deficits.

    Abstract

    Pramiracetam (CI-879; N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide; CAS 68497-62-1; molecular formula C14H27N3O2; molecular weight 269.39 g/mol) is a second-generation nootropic of the racetam class, synthesized at Parke-Davis in the late 1970s as a structural analog of piracetam. The compound differs from piracetam by replacement of the primary amide group with a diisopropylaminoethyl amide, a modification that substantially increases lipophilicity, central nervous system penetration, and effective potency, permitting therapeutic doses approximately five to ten times lower than equivalent piracetam regimens. Pramiracetam was advanced through preclinical and clinical development at Parke-Davis (then a division of Warner-Lambert, subsequently acquired by Pfizer) with the development code CI-879. The compound was licensed to Menarini for European development and was marketed under the trade names Pramistar, Neupramir, and Remen in Italy, Belgium, and several Eastern European jurisdictions for the treatment of memory and attention deficits in aging populations with neurodegenerative and vascular dementias. The Italian marketing authorization under Menarini was maintained until 2020, when it was voluntarily withdrawn by the manufacturer. The principal pharmacological mechanism of pramiracetam, characterized in the Pugsley et al. (1983) and subsequent studies, is selective enhancement of high-affinity choline uptake (HACU) in hippocampal and cortical cholinergic nerve terminals [1]. HACU is the rate-limiting step in acetylcholine biosynthesis; pramiracetam increases the velocity of choline transport into presynaptic cholinergic neurons without altering monoamine neurotransmitter concentrations, receptor binding profiles at dopaminergic, serotonergic, adrenergic, or histaminergic sites, or monoamine oxidase activity. The selectivity of the HACU mechanism distinguishes pramiracetam from piracetam, which acts predominantly through AMPA receptor positive allosteric modulation and membrane fluidity enhancement. Additional preclinical findings include increased nitric oxide synthase activity in rat cerebral cortex following systemic administration [2] and normalization of age-related electroencephalographic abnormalities in aged Fischer-344 rats [3]. The compound does not exhibit direct cholinesterase inhibition, muscarinic or nicotinic receptor agonism, or GABAergic activity at pharmacologically relevant concentrations. Pharmacokinetics in healthy human volunteers are characterized by rapid oral absorption, with peak plasma concentrations attained in approximately two to three hours; a plasma elimination half-life of 4.5 to 6.5 hours; linear dose-proportional exposure across the studied dose range (400 to 1600 mg); negligible plasma protein binding; and predominantly renal excretion of unchanged drug with minimal hepatic metabolism [4, 5]. The absence of significant cytochrome P450 involvement reduces drug-drug interaction liability relative to hepatically metabolized nootropic and cholinergic agents. The clinical evidence base includes a two-phase placebo-controlled trial in probable Alzheimer disease conducted at the National Institutes of Neurological Disorders and Stroke (Claus et al., 1991), which found that doses up to 4000 mg daily were unlikely to confer symptomatic benefit in moderate-to-severe Alzheimer disease [6]; a placebo-controlled study of scopolamine-induced amnesia in healthy volunteers demonstrating partial reversal of anticholinergic memory impairment in both young and elderly subjects [7]; a small open-label study in traumatic brain injury rehabilitation showing improved cognitive recovery [8]; and the European registration trials conducted by Menarini supporting the indication for memory and attention deficits in elderly patients with neurodegenerative and vascular dementias. Effect sizes across these studies are consistently small to moderate, and the compound has not produced a positive Phase 3 registration-quality readout in Alzheimer disease. Pramiracetam is not approved by the United States Food and Drug Administration and is classified as an unapproved new drug in the United States. It is available as a research-grade chemical from multiple suppliers. This monograph documents the chemistry, synthesis, and structural pharmacology of pramiracetam; the high-affinity choline uptake mechanism and supporting preclinical pharmacology; the comprehensive human pharmacokinetic record; the clinical evidence base across cognitive indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications for research use; adverse-event signal; and a structured comparative assessment of five racetam-class and cholinergic nootropic compounds against pramiracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1429Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Centrophenoxine (Meclofenoxate)

    Plain-language summaryIntrigue 56 / 100

    Centrophenoxine is an ester of DMAE that crosses into the brain to support cognitive function and remove lipofuscin (cellular waste pigment). Used historically for age-related cognitive decline. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Cholinergic precursor ester combining dimethylaminoethanol and 4-chlorophenoxyacetic acid with lipofuscin-clearing and neuroprotective activity

    A synthetic ester of dimethylaminoethanol and para-chlorophenoxyacetic acid developed in 1959 at the French National Scientific Research Center, distinguished from other cholinergic precursors by its capacity to reduce neuronal lipofuscin accumulation and to enhance phospholipid membrane turnover in aging brain tissue.

    Abstract

    Centrophenoxine (meclofenoxate, Lucidril; 2-(dimethylamino)ethyl (4-chlorophenoxy)acetate; CAS 51-68-3; molecular formula C12H16ClNO3; molecular weight 257.71 g/mol) is a synthetic cholinergic precursor and neuroprotective agent developed in 1959 at the Centre National de la Recherche Scientifique (CNRS) in France. The compound is an ester of two biologically active moieties: dimethylaminoethanol (DMAE), a naturally occurring aminoalcohol found in small quantities in the human brain and implicated in choline and phospholipid metabolism, and para-chlorophenoxyacetic acid (pCPA), a synthetic auxin derivative that serves as a lipophilic carrier facilitating blood-brain barrier penetration and extending the biological half-life of the DMAE component. Following oral administration, centrophenoxine undergoes rapid hepatic ester hydrolysis to release DMAE and pCPA. The DMAE moiety is subsequently methylated to choline, which enters the acetylcholine synthetic pathway and is incorporated into membrane phospholipids as phosphatidyldimethylaminoethanol and phosphatidylcholine. The compound’s most distinctive pharmacological feature is the reduction of lipofuscin, the heterogeneous age pigment that accumulates progressively in postmitotic cells including cortical and hippocampal neurons, cardiac myocytes, and retinal pigment epithelium. The lipofuscin-clearing activity was first demonstrated by Nandy and Bourne in 1966 in senile guinea pig neurons and has been replicated across multiple rodent species, with reductions of 25 to 40 percent in cortical and hippocampal lipofuscin content following chronic oral administration at doses of 40 to 80 mg/kg/day for three to six months [1, 2]. The mechanism of lipofuscin clearance is incompletely characterized but is attributed to a combination of enhanced lysosomal enzyme activity, increased membrane phospholipid turnover (which dilutes the lipofuscin granule burden through membrane remodeling), and direct free radical scavenging by the DMAE moiety, which is incorporated into neuronal membranes as phosphatidyl-DMAE and functions as a hydroxyl radical scavenger [3, 4]. The clinical evidence base in human cognitive impairment spans approximately five decades but is modest in scale and quality by contemporary standards. The largest double-blind, randomized, placebo-controlled trial in healthy elderly subjects (Marcer and Hopkins, 1977; n = 50) demonstrated significant improvement in delayed free recall after three months of oral centrophenoxine at 600 mg twice daily, with no effect on immediate recall, digit span, or recognition memory, suggesting a selective enhancement of memory consolidation into long-term storage [5]. A second double-blind trial in 50 patients with organic dementia (Pek and Fulop, 1983) reported improvement in 48 percent of centrophenoxine-treated subjects versus 28 percent on placebo, although with high variability and methodological limitations [6]. Smaller open-label and controlled studies have reported improvements in vigilance, reaction time, and subjective mental alertness in elderly populations. The compound is marketed as a prescription medicine in several European countries (France, Germany, Hungary, Austria), in Japan, and in parts of Latin America for indications including senile cognitive impairment, post-stroke cognitive rehabilitation, and alcohol-related cognitive decline. It is not approved by the United States Food and Drug Administration and is sold as a research chemical in the United States. Pharmacokinetics are characterized by rapid oral absorption, rapid hepatic ester hydrolysis (plasma half-life of the parent ester is approximately 30 to 60 minutes), and a longer effective duration attributable to the persistence of the DMAE metabolite in brain tissue. Typical clinical doses range from 600 to 2000 mg per day in two or three divided administrations. The adverse-event profile is favorable; the most commonly reported effects are mild gastrointestinal discomfort, insomnia, and headache, generally at higher doses and resolving with dose reduction. This monograph reviews the chemistry, synthesis, and structural pharmacology of centrophenoxine; the lipofuscin-clearing, cholinergic, antioxidant, and membrane-modifying mechanisms; the pharmacokinetic profile; the preclinical and clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions with racetams and other cholinergic agents; the adverse-event and safety profile; and a comparative assessment of five cholinergic and neuroprotective alternatives (alpha-GPC, citicoline, DMAE, piracetam, and idebenone) against centrophenoxine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1445Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Halothane

    Plain-language summaryIntrigue 50 / 100

    Halothane was the first clinically successful non-flammable halogenated volatile anesthetic, synthesized at ICI in 1951 and dominant from 1956 through the 1980s. It displaced the dangerous flammable agents (diethyl ether, chloroform) that preceded it. The blood-gas partition coefficient of 2.4 is slow by modern standards, and the mechanism is the standard volatile anesthetic profile (GABA-A, K2P, glycine, NMDA). Two issues drove its retirement: halothane hepatitis, an immune-mediated necrosis tied to trifluoroacetyl protein adducts generated by 20 percent hepatic metabolism (incidence around 1 in 35,000), and a cardiovascular profile featuring myocardial depression and sensitization to catecholamine arrhythmias. Still the dominant inhalational anesthetic in lower-resource settings owing to acquisition cost (about a third of isoflurane). Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Halogenated alkane volatile general anesthetic

    The first clinically successful non-flammable halogenated volatile anesthetic, dominant from 1956 through the 1980s, displaced by ether-class agents owing to halothane hepatitis.

    Abstract

    Halothane (2-bromo-2-chloro-1,1,1-trifluoroethane; CAS 151-67-7; molecular formula C2HBrClF3; molecular weight 197.38) is a halogenated alkane volatile anesthetic synthesized by Charles Suckling at ICI in 1951 and introduced clinically by Michael Johnstone in 1956. Halothane was the first non-flammable volatile to displace diethyl ether and chloroform as the dominant inhalational agent and remained in widespread use through the 1980s before isoflurane and the newer ethers superseded it. The minimum alveolar concentration (MAC) at age 40 is 0.75 percent in oxygen; the blood-gas partition coefficient is 2.4, slower than the modern ether agents. Mechanism is the standard volatile profile (GABA-A potentiation, K2P channel activation, glycine and NMDA modulation). Cardiovascular effects include dose-dependent myocardial depression with preserved or modestly reduced systemic vascular resistance, sensitization to catecholamine-induced arrhythmias (a clinically important interaction with epinephrine), and bradyarrhythmia. The principal limitations that drove displacement are halothane hepatitis (immune-mediated hepatic necrosis with an incidence of approximately 1 in 35,000 cases, attributed to trifluoroacetyl protein adducts generated by 20 percent hepatic metabolism through CYP2E1), and the negative inotropic and arrhythmogenic profile relative to the ether agents. Halothane remains the dominant inhalational anesthetic in lower-resource settings owing to acquisition cost (manufacturer-stated cost approximately one-third of isoflurane). Veterinary use persists in some jurisdictions. The global warming potential is moderate (GWP100 approximately 50). Pediatric induction was a historical strength owing to the non-pungent character; sevoflurane has displaced halothane for this indication in most jurisdictions.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1304Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Methohexital

    Plain-language summaryIntrigue 55 / 100

    Methohexital sodium (Brevital) is an ultrashort-acting methylated oxybarbiturate introduced by Eli Lilly in 1960. It differs from thiopental in retaining oxygen at the 2-position (oxybarbiturate, not thiobarbiturate) and adding a methyl group on the N-1 nitrogen. The 1-methyl substitution speeds hepatic metabolism roughly four-fold, shortening elimination half-life to about four hours and giving faster awakening with minimal residual sedation after a single induction dose. The dominant modern use is electroconvulsive therapy: methohexital is the preferred ECT induction agent in many practices because it has minimal anticonvulsant effect at induction doses, while propofol and thiopental both raise seizure threshold and shorten ECT seizures. Cardiovascular and respiratory effects mirror thiopental. Standard barbiturate cautions apply (porphyria, the 1-methyl group does not eliminate porphyrinogenicity). Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Methylated oxybarbiturate intravenous anesthetic

    An ultrashort-acting methylated oxybarbiturate with faster recovery than thiopental, used principally for electroconvulsive therapy and brief procedural anesthesia.

    Abstract

    Methohexital sodium (alpha-DL-1-methyl-5-allyl-5-(1-methyl-2-pentynyl)barbituric acid sodium; CAS 22151-68-4; molecular formula C14H17N2NaO3; molecular weight 284.29 free acid) is a methylated oxybarbiturate intravenous anesthetic synthesized by Eli Lilly in 1956 and introduced clinically as Brevital in 1960. The compound differs from thiopental in retaining oxygen at the 2-position (oxybarbiturate rather than thiobarbiturate) and carrying a methyl group on the N-1 nitrogen. The 1-methyl substitution accelerates hepatic metabolism (clearance approximately 4-fold faster than thiopental on a milligram basis) and shortens elimination half-life to approximately 4 hours, enabling faster awakening with minimal residual sedation after a single induction dose. Mechanism is GABA-A positive allosteric modulation at the barbiturate site, identical to thiopental. The principal clinical niches in modern practice are electroconvulsive therapy (where the brief duration enables rapid recovery in serial-ECT outpatient settings) and brief procedural sedation in patients with contraindications to propofol. Methohexital is the dominant induction agent for ECT in many practices owing to its minimal anticonvulsant effect at induction doses (versus propofol and thiopental, which raise seizure threshold and shorten ECT seizure duration, requiring higher electrical stimulus). Cardiovascular and respiratory effects are similar to thiopental. The principal historical safety concerns are myoclonus on injection (a propofol-class adverse event also seen with methohexital) and the standard barbiturate contraindications (porphyria; the 1-methyl substitution does not eliminate the porphyrinogenic effect). Maximum recommended dose for induction is 1 to 1.5 mg/kg.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1321Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Larazotide

    Zonulin antagonist octapeptide and tight junction modulator

    An eight-residue zonulin receptor antagonist developed by Innovate Biopharmaceuticals (now 9 Meters Biopharma) as the first specific gut tight junction modulator advanced to Phase 3 in celiac disease.

    Abstract

    Larazotide acetate (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly; CAS 258818-34-7; molecular weight 754.86 free peptide) is an eight-residue synthetic peptide developed at the University of Maryland by Alessio Fasano and colleagues as a competitive antagonist at the zonulin receptor. Zonulin (also designated pre-haptoglobin 2) is the human ortholog of the Vibrio cholerae zonula occludens toxin (ZOT) and is the only known endogenous regulator of intestinal epithelial tight junction permeability; activation of the zonulin pathway in response to gluten exposure or other triggers produces transient opening of intestinal tight junctions and translocation of luminal antigens into the lamina propria, contributing to celiac disease pathogenesis and a broader leaky-gut phenotype implicated in autoimmune and inflammatory conditions. Larazotide binds the zonulin receptor and blocks ZOT/zonulin-induced tight junction disassembly without directly affecting baseline tight junction integrity. The compound was advanced through Phase 1 and Phase 2 trials in celiac disease and entered Phase 3 (CeDLara) for the residual gluten-cross-contamination phenotype in patients on a gluten-free diet who continue to experience symptoms. The Phase 3 readout in 2022 did not meet the primary endpoint of celiac disease patient-reported outcome, and 9 Meters Biopharma announced discontinuation of the program. Despite the clinical setback in celiac disease, larazotide remains a pharmacologically distinct research tool for tight junction modulation in inflammatory bowel disease, multiple sclerosis, and other indications where intestinal barrier dysfunction is implicated. Oral bioavailability is essentially zero (the peptide acts in the gut lumen and is not absorbed); the route of administration is per oral as a sustained-release formulation. Adverse events in clinical trials were mild and dominated by gastrointestinal effects.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1336Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • GTS-21

    Alpha-7 nicotinic acetylcholine receptor partial agonist with alpha-4-beta-2 cross-reactivity, derivative of the natural marine alkaloid anabaseine

    A 3-(2,4-dimethoxybenzylidene)anabaseine derivative of the marine nemertine-worm alkaloid anabaseine, characterized in the laboratory of William Kem at the University of Florida and advanced through Phase 1 and Phase 2 clinical development for schizophrenia cognitive impairment, Alzheimer disease, and selected exploratory cognitive endpoints. The longest-studied alpha-7 nicotinic partial agonist in cognitive applications and the principal historical reference compound for the receptor class.

    Abstract

    GTS-21 (also known as DMXBA, DMBX-anabaseine, and 3-(2,4-dimethoxybenzylidene)anabaseine) is a small-molecule partial agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor. The compound is a synthetic derivative of the natural product anabaseine, a marine alkaloid originally isolated from nemertine ribbonworms and from certain ant species, characterized chemically and pharmacologically by William Kem at the University of Florida beginning in the late 1970s. Anabaseine itself is a non-selective nicotinic receptor agonist with substantial muscle-type alpha-1 nicotinic activity that produces neuromuscular toxicity at doses producing central nervous system effects. The 3-(2,4-dimethoxybenzylidene) substitution at the anabaseine scaffold (the structural feature defining DMXBA) substantially increases alpha-7 nicotinic receptor selectivity over the muscle-type receptor and produces the partial agonist functional profile that has supported clinical development. Functional intrinsic activity at human alpha-7 nicotinic receptors expressed in heterologous systems is approximately 30 to 50 percent of the acetylcholine maximum response. Selectivity over the alpha-4-beta-2 nicotinic subtype is incomplete: GTS-21 binds alpha-4-beta-2 with affinity comparable to alpha-7 and acts as a partial agonist at alpha-4-beta-2 in some functional assays and as an antagonist in others, contributing complexity to the in vivo pharmacology that distinguishes GTS-21 from the more selective subsequent candidates encenicline, bradanicline, and PHA-543613. The compound is the longest-studied alpha-7 nicotinic partial agonist in cognitive applications, with continuous research from the early 1990s through the 2020s, and is the principal historical reference compound for the receptor class. GTS-21 was advanced through multiple Phase 1 studies in healthy volunteers in the 1990s and 2000s with positive cognitive signals (the original Kitagawa et al. 2003 healthy volunteer report demonstrated improvements on the Connors Continuous Performance Test), through several Phase 2 studies in schizophrenia cognitive impairment (Olincy et al. 2006 immediate-release proof-of-concept; Olincy et al. 2017 extended-release confirmatory), and through Phase 2 studies in Alzheimer disease and other exploratory cognitive indications. The clinical results have been consistent with a small effect size that produced significant signals in some early studies and not in subsequent larger studies. The compound is metabolized to two principal active metabolites (4-OH-GTS-21 and 2-OH-GTS-21) that retain alpha-7 nicotinic partial agonist activity and contribute to the pharmacodynamic profile; the metabolite contribution complicates the dose-response interpretation and was the principal motivation for the extended-release formulation tested in the Olincy 2017 study. The compound is not in active commercial development as of the most recent monograph revision; research-grade GTS-21 is widely available and continues to be used as a reference alpha-7 partial agonist in fundamental pharmacology. This monograph reviews the chemistry, anabaseine biosynthesis, structural class of GTS-21; the receptor pharmacology including the alpha-4-beta-2 cross-reactivity; the comprehensive human pharmacokinetic record including the active metabolite contribution; the clinical evidence base across schizophrenia, Alzheimer disease, healthy volunteer cognition, and selected inflammatory indications; and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against GTS-21.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1355Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.